Glaukos (GKOS) continues to benefit from a robust product portfolio and favorable clinical trial results.
BD's (BDX) robust product portfolio raises optimism about the stock.
Patterson Companies' (PDCO) Patterson CarePay+ is likely to improve overall patient care and streamline practice operations.